Vimarsana
Biggest News Aggregation in the World

Page 10 - Director Simon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director Simon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Simon Today - Breaking & Trending Today

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Boosted by Driehaus Capital Management LLC - Vimarsana News

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Boosted by Driehaus Capital Management LLC

Driehaus Capital Management LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,681,797 shares of the biopharmaceutical company’s stock after acquiring an additional 177,777 shares during the period. Xenon Pharmaceuticals comprises about 2.8% of Driehaus Capital Management LLC’s holdings, […]

Simon Copland | ACT government Northbourne Avenue 40kmh speeding windfall should be spent on safety | The Canberra Times - Vimarsana News

Simon Copland | ACT government Northbourne Avenue 40kmh speeding windfall should be spent on safety | The Canberra Times

We want slower streets, but Northbourne changes is all wrong.

Simon Copland | ACT government Northbourne Avenue 40kmh speeding windfall should be spent on safety | The Canberra Times - Vimarsana News

Simon Copland | ACT government Northbourne Avenue 40kmh speeding windfall should be spent on safety | The Canberra Times

We want slower streets, but Northbourne changes is all wrong.

Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at StockNews.com - Vimarsana News

Xenon Pharmaceuticals (NASDAQ:XENE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a research note released on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on XENE. Needham & Company LLC reissued a buy rating and set a $50.00 target […]

StockNews.com Begins Coverage on Xenon Pharmaceuticals (NASDAQ:XENE) - Vimarsana News

StockNews.com Begins Coverage on Xenon Pharmaceuticals (NASDAQ:XENE)

StockNews.com started coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a research report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the stock. Stifel Nicolaus upped their target price on shares of Xenon Pharmaceuticals from $52.00 to $53.00 […]